Urothelial carcinoma, or transitional cell carcinoma, is the most common bladder cancer and grows in the urothelial cells lining the urinary tract.

Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.

In Urothelial Carcinoma, How Do Variant Histologies Impact Survival? —These investigators analyzed clinicopathological and outcomes data to better categorize the effects of 9 different types of ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

Metastatic Upper Tract Urothelial Carcinoma: Quality Care Severely Lacking —This retrospective cohort study of mUTUC patients aged 66 or older from the SEER-Medicare database showed that less ...

Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...

Conclusions Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation.

A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.

Overall, "uCGP enables noninvasive, accurate urothelial carcinoma diagnosis and risk stratification in both hematuria and urothelial carcinoma surveillance patients," the authors conclude.

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

Gilead has made the decision to withdraw the accelerated approval of Trodelvy ® (sacituzumab govitecan-hziy) for metastatic urothelial cancer in the US.